Cardiovascular-kidney-metabolic (CKM) health — why we look at these together

In brief

• Excess body fat, diabetes, high blood pressure, abnormal cholesterol, kidney disease and heart disease are linked expressions of one process: CKM syndrome.
• Each drives the next, so we assess and treat the whole cluster, not one condition at a time.
• Some medicines, such as SGLT2 inhibitors and GLP-1 receptor agonists, work across several of these conditions at once.
• Lifestyle is the foundation: 150–300 minutes of activity a week plus 2 resistance sessions, and a 5–10% weight loss is clinically meaningful.
• In Asians, risk rises at a lower weight: a BMI of 23, or a waist of 90 cm in men and 80 cm in women.

We review the whole CKM picture at our Punggol clinic. See our chronic disease care.

What is CKM syndrome?

The American Heart Association’s 2023 Presidential Advisory describes CKM syndrome as a framework linking:

• Excess or dysfunctional body fat: not just BMI, but where the fat is stored and how metabolically active it is
• Metabolic risk factors: high blood glucose or diabetes, high blood pressure, and abnormal lipids
• Chronic kidney disease: reduced filtering function and/or protein leaking into the urine
• Cardiovascular disease: coronary artery disease, heart failure, stroke, peripheral vascular disease and atrial fibrillation

These conditions don’t run in parallel; they are different expressions of a single underlying process. Dysfunctional fat drives insulin resistance. Insulin resistance drives diabetes and hypertension, which drive kidney damage. Kidney damage drives cardiovascular risk, and cardiovascular disease drives heart failure. Each step amplifies the next.

Treating blood sugar while ignoring the kidneys, weight or blood pressure misses most of the leverage. A well-designed plan addresses the cluster.

Why these systems drive each other

The main mechanisms, in broad strokes:

• Dysfunctional fat tissue: visceral fat (inside the abdomen, around the organs) and ectopic fat (in the liver, muscle, pancreas and heart) are metabolically active in ways subcutaneous fat is not. They release inflammatory molecules and free fatty acids that interfere with insulin elsewhere in the body.
• Insulin resistance: the earliest measurable step. The body needs ever more insulin to do the same job, and the high insulin itself drives sodium retention (raising blood pressure), lipid changes (higher triglycerides, lower HDL) and more fat storage.
• An overactive renin-angiotensin-aldosterone system (RAAS): this hormone system regulates blood pressure and fluid balance. Overactivated, it raises blood pressure, damages small vessels and promotes kidney injury.
• Chronic low-grade inflammation injures blood vessel walls and speeds up atherosclerosis.
• Oxidative stress: excess reactive molecules damage cells, including the kidney’s filtering units and the endothelial lining of blood vessels.
• Cardiorenal cross-talk: a failing heart reduces blood flow to the kidneys, and kidney dysfunction drives fluid retention that worsens heart failure.

The practical point: what improves one part of this system, whether a habit or a medicine, often improves the others too.

The CKM stages — where you are on the spectrum

The AHA framework has five stages. We rarely label patients with a stage number, but the ladder explains why we assess what we assess.

Stages aren’t one-way. With good management, especially early, many people at stage 1 or early stage 2 regress through targeted lifestyle change and well-chosen medication.

An Asian-specific point: the adiposity cut-offs that define Stage 1 are lower in Asian than in European populations. A BMI of 23 (not 25) already marks increased risk in most Asian groups, and the waist thresholds are 90 cm for men and 80 cm for women. So we watch weight and waist even in people who don’t look “overweight” by Western standards.

Risk prediction — the PREVENT framework

In 2023 the AHA also released the PREVENT (Predicting Risk of cardiovascular disease EVENTs) equations. They estimate 10- and 30-year cardiovascular risk and were designed to replace older tools such as the Pooled Cohort Equations. What’s different:

• They apply to a much broader age range (30 to 79 years).
• They include kidney function (eGFR), which earlier calculators didn’t.
• They accept albuminuria and HbA1c as optional inputs, making them more sensitive for CKM-heavy patients.
• They remove race as a risk multiplier, a significant methodological shift.
• They give a 30-year risk as well as the usual 10-year figure. This helps younger patients, whose 10-year risk can look reassuring while the long-run trajectory is concerning.

In Singapore, we still use the SG-FRS-2023 (Singapore-modified Framingham Risk Score) as our main calculator, because it is calibrated to local event rates. PREVENT is a useful complement, especially for younger patients and when kidney function is in question. We may use either, or both, with you. For targets and statin decisions, see our cholesterol and statins guide.

What this changes in your visits with us

A CKM-informed review looks at the whole person rather than a single organ. It typically covers:

• weight, BMI and waist circumference, because adiposity sits upstream of much of the rest
• blood pressure, ideally with home readings
• fasting glucose or HbA1c, and any family history of diabetes
• lipid panel: LDL, HDL, triglycerides, non-HDL
• eGFR and urine albumin-to-creatinine ratio (UACR); the urine test matters because significant albuminuria can exist with a normal eGFR
• smoking status and any vaping
• sleep quality and screening for obstructive sleep apnoea, an under-recognised CKM driver
• a short check on mood, stress and social context, which affect adherence and lifestyle
• vaccination status: flu, pneumococcal, shingles, hepatitis B (especially if moving towards advanced CKD), COVID

We track this list over a year rather than at every visit. Use it to prompt us if something hasn’t been reviewed for a while.

Why we cross-check. If blood pressure is the headline, we still ask about glucose and kidney function. Hypertension is often an early CKM signal, and the kidneys rarely stay untouched when blood pressure is high. The same applies to every component: one test in isolation gives a misleadingly narrow view.

Medications that work across the cluster

Several medicine classes from the last decade genuinely work across multiple CKM components at once.

SGLT2 inhibitors (dapagliflozin — Forxiga; empagliflozin — Jardiance)

First developed for diabetes, they now have proven benefit in:

• Diabetes: lower glucose, modest weight loss, low hypoglycaemia risk
• Heart failure: fewer hospitalisations and deaths, with both preserved and reduced ejection fraction
• Chronic kidney disease: slower decline in kidney function and less progression to kidney failure, with or without diabetes
• Blood pressure: a small but consistent reduction
• Weight: typically 2–3 kg

Acting on four CKM components at once is unusual for one class.

GLP-1 receptor agonists (semaglutide — Ozempic/Wegovy; dulaglutide — Trulicity; liraglutide — Victoza)

First used for diabetes, now used well beyond it:

• Diabetes: strong glucose lowering, low hypoglycaemia risk
• Weight management: 10–17% body weight loss at higher doses (Wegovy-branded semaglutide is registered specifically for weight)
• Cardiovascular risk: fewer major cardiovascular events in high-risk patients, including those without diabetes
• Emerging kidney benefit: the recent FLOW trial (semaglutide) showed a 24% reduction in the composite kidney outcome in people with CKD and type 2 diabetes
• Metabolic-associated steatotic liver disease (MASLD/MASH): less liver fat and fibrosis

Tirzepatide (Mounjaro)

A newer dual GIP/GLP-1 receptor agonist. It gives even greater weight loss than GLP-1 alone (often 18–22%), with strong glucose effects and emerging cardiovascular data. In Singapore it is registered as Mounjaro for type 2 diabetes, and for weight management in adults with obesity, or with overweight plus a weight-related condition.

Finerenone (Kerendia)

A non-steroidal mineralocorticoid receptor antagonist. In diabetic kidney disease, added to ACEi/ARB and an SGLT2 inhibitor, it reduces both cardiovascular and kidney outcomes. It is registered in Singapore for this use, and since November 2025 eligible patients can get it subsidised through the Medication Assistance Fund when a specialist starts it or advises on it. We would discuss it as a later add-on in the right patient.

ACE inhibitors and ARBs

The foundation blood pressure class for anyone with albuminuria, kidney disease or heart failure, or after a heart attack. Benefits span blood pressure, kidney protection and fewer cardiovascular events.

Statins

The cornerstone of lipid lowering, with established cardiovascular mortality benefit. Safe in kidney disease, with dose adjustment in later stages. Details in our cholesterol and statins guide.

Metformin

The first-line diabetes medicine for most patients: decades of safety data, some cardiovascular benefit, low hypoglycaemia risk and minimal cost.

The polypharmacy question

Someone with advanced CKM might take an ACEi or ARB, a statin, metformin, an SGLT2 inhibitor and a GLP-1 RA, and possibly finerenone, a beta-blocker or calcium channel blocker, and aspirin. That is genuinely a lot of tablets.

Each has strong trial evidence for that risk profile and protects part of the CKM cluster, so none is “extra”. But cost, timing, tolerability and pill burden need discussion. We’d rather you took a simpler regimen reliably than had an optimal one sitting unused in your cabinet.

We usually start with the most impactful single medicine for your picture, add one step at a time, review at 2–3 months, and adjust. We explain what each drug does; ask if you’re not sure.

Lifestyle — the foundation under all of it

Lifestyle is the foundation medicines are built on. Without it, they give smaller gains and more side effects.

Food pattern

A Mediterranean or DASH (Dietary Approaches to Stop Hypertension) style pattern has the strongest evidence for lowering CKM risk, adapted to local eating:

• More plants: vegetables, fruit, wholegrains, beans, nuts and seeds
• Healthy fats: olive oil, nuts, seeds, fatty fish
• Less refined carbohydrate: white rice and bread are local staples; smaller portions, mixed with brown rice, quinoa or oats, lower the glycaemic load
• Moderate protein: fish, tofu, lean meat, eggs, dairy
• Less processed and ultra-processed food, which quietly pushes up sodium, sugar and saturated fat
• Less added sugar and fewer sugar-sweetened drinks: kopi-si kosong is a practical switch
• Less saturated fat, particularly in processed foods
• Reasonable salt: under 2 g of sodium a day. The Health Promotion Board’s online sodium tool is useful in Singapore because hawker-dish sodium varies so much between vendors.

Physical activity

• 150–300 minutes a week of moderate-intensity activity (brisk walking, cycling, swimming), plus 2 resistance sessions a week
• Activity works across the cluster. It lowers blood pressure, improves insulin sensitivity and lipids, supports weight and sleep, and reduces cardiovascular events independently of weight change.
• Movement matters even without weight loss; “not thin yet” is no reason to stop.

Weight

• A 5–10% weight reduction is clinically meaningful across all CKM components.
• 15% or more, increasingly achievable with GLP-1 RAs and tirzepatide, brings extra benefit, including possible remission of type 2 diabetes and meaningful improvement in MASLD.
• Stable weight loss over 12–18 months beats rapid loss followed by regain.

Sleep

• Aim for 7–9 hours a night.
• Screen for obstructive sleep apnoea in anyone with hypertension, heart failure, atrial fibrillation or significant obesity. OSA drives CKM risk and is readily treatable.
• Shift work and chronic sleep restriction are under-appreciated CKM amplifiers.

Stress and mental health

Chronic stress, untreated anxiety or depression, and social isolation raise CKM risk through cortisol, sympathetic activation and behaviour (eating, sleep, activity). We often include a brief mood screen and refer for psychological support where needed.

Smoking and alcohol

• Stopping smoking is the single most impactful change at any age. The I Quit national programme and medicines (nicotine replacement, varenicline, bupropion) are available; ask at your visit.
• Alcohol within moderate limits (no more than 2 standard drinks a day for men, 1 for women) is acceptable for most people. Less is better for blood pressure and liver health.

Shared decision-making when priorities compete

CKM care often involves trade-offs. Some common situations:

• A frail older patient with CKD, hypertension and diabetes. We may prefer softer targets (BP <140/90, HbA1c up to 8%, LDL <2.6), because over-treatment brings real risks at that age: low blood pressure, falls, hypoglycaemia.
• A young patient at early stage 2 (prediabetes, mild hypertension, borderline lipids). The biggest gains usually come from sustained lifestyle change and careful single-agent medication. Starting five drugs at once is usually the wrong move; starting two, reviewing at 3–6 months and adding more if needed is usually right.
• Someone who genuinely can’t tolerate multiple medicines. Drug order and class choice matter. We often start with the agent giving the biggest benefit for the leading risk: an SGLT2 inhibitor for diabetes with CKD, a GLP-1 RA where weight dominates, an ACE inhibitor for albuminuria or heart failure.
• Someone in an acute life transition, such as bereavement, a job change or caregiver burden. This is often the wrong time to change half their medicines; we revisit in a few months.

Shared decision-making is a practical necessity here. People reasonably weigh priorities differently, and your plan should reflect yours.

When specialist input helps

Most CKM care is well managed in primary care. Shared or specialist care becomes valuable for:

• Advanced CKD, G3b and beyond (see our CKD guide)
• Established cardiovascular disease needing specialist follow-up: recent heart attack, significant heart failure, complex arrhythmias, severe peripheral vascular disease
• Diabetes needing complex regimens, such as type 1, brittle type 2, or decisions on insulin pumps or continuous glucose monitoring
• Significant obesity being considered for bariatric or metabolic surgery, where eligibility and pre-assessment usually need endocrinologist or bariatric team input
• Secondary or resistant hypertension, worth investigating when standard regimens don’t achieve control
• Unusual or autoimmune contributors: SLE, vasculitis, primary renal disease
• Complex lipid disorders: familial hypercholesterolaemia, or severe hypertriglyceridaemia needing specialist lipid clinic input

Shared care doesn’t mean we hand you over; we coordinate with the specialist and continue your core long-term care. Most patients benefit from one doctor who holds the whole picture, often a family physician.

The Singapore context

• Healthier SG Chronic Tier (February 2024 onwards): enrolled patients get common chronic medicines (including ACEi/ARBs, statins, metformin, selected SGLT2 inhibitors and GLP-1 RAs) at prices close to polyclinic rates, for long-term care with their chosen GP.
• Community Health Assist Scheme (CHAS): means-tested subsidies for consultations and selected medicines at participating GP clinics. More at chas.sg.
• MediSave: for chronic disease consultations and selected medicines, up to the annual limit (currently $500, or $700 for complex chronic conditions; rising to $700 / $1,000 from January 2027).
• Healthier SG: the national preventive framework emphasises this whole-person review. Enrolling with us lets us track the cluster over time rather than see you episodically.
• Allied health and counselling, through Primary Care Networks and the wider MOH preventive care system.

The bottom line

If you have one CKM condition, you almost certainly have early features of others. If you have three or four, you are in the cluster, and it responds meaningfully to coordinated care. Our job in primary care is to hold the whole picture:

• track the numbers that matter
• flag the trends we don’t like
• choose medicines that work across several components
• support the lifestyle foundation
• match intensity to your circumstances and preferences

That isn’t “more medicine”. It’s more targeted medicine, with fewer blind spots.

Get in touch

Punggol — 658 Punggol East, #01-04, Singapore 820658 · Tel 6312 4589

Joo Chiat — 172 Joo Chiat Road, #01-01, Singapore 427443 · Tel 6920 1952

Email — admin@ktmc.sg

References

Framework and staging

• Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–1635. doi.org/10.1161/CIR.0000000000001184
• Ndumele CE, Neeland IJ, Tuttle KR, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2023;148(20):1636–1664.

Risk prediction

• Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) Equations. Circulation. 2024;149(6):430–449.
• Singapore-modified Framingham Risk Score 2023 (SG-FRS-2023). cvd.clinicaltools.mohtgroup.com

Pharmacotherapy across CKM

• Packer M, Anker SD, Butler J, et al. (EMPEROR-Preserved). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451–1461.
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. (DAPA-CKD). Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436–1446.
• EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117–127.
• Wilding JPH, Batterham RL, Calanna S, et al. (STEP-1). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.
• Perkovic V, Tuttle KR, Rossing P, et al. (FLOW Trial). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109–121.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216.
• Bakris GL, Agarwal R, Anker SD, et al. (FIDELIO-DKD). Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219–2229.

Singapore registration and subsidy

• National Drug Formulary, Ministry of Health, Singapore. Mounjaro solution for injection in vial 15 mg/0.5 mL (SIN17356P) — product information. ndf.gov.sg
• National Drug Formulary, Ministry of Health, Singapore. Kerendia film-coated tablet 10 mg (SIN16387P) — product information. ndf.gov.sg
• Agency for Care Effectiveness (ACE). Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes. Technology Guidance from the MOH Drug Advisory Committee. Updated 16 September 2025. ace-hta.gov.sg

Asian-adjusted adiposity thresholds

• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.

National programmes

• Ministry of Health, Singapore. Healthier SG and Chronic Tier information. healthiersg.gov.sg
• Community Health Assist Scheme. chas.sg
• Health Promotion Board Singapore. Food Composition Online Search. focos.hpb.gov.sg

This information is for general education only and is not a substitute for medical advice. CKM management is individualised to the pattern and severity of each person’s risk factors, preferences, and life circumstances — please speak with our team about what’s right for you. v1.1 · October 2026 (v1.0 April 2026) · Review due April 2028.